Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed/refractory multiple myeloma

Publication ,  Conference
Kang, Y; Neff, J; Gasparetto, C; Wang, X; Ellero, A; Walker, C
Published in: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
2023

Duke Scholars

Published In

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

EISSN

2152-2669

ISSN

2152-2650

Publication Date

2023

Volume

23

Start / End Page

S259 / S259

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kang, Y., Neff, J., Gasparetto, C., Wang, X., Ellero, A., & Walker, C. (2023). Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed/refractory multiple myeloma. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 23, pp. S259–S259).
Kang, Yubin, Jadee Neff, Cristina Gasparetto, Xiaobei Wang, Andrea Ellero, and Christopher Walker. “Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed/refractory multiple myeloma.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 23:S259–S259, 2023.
Kang Y, Neff J, Gasparetto C, Wang X, Ellero A, Walker C. Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed/refractory multiple myeloma. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023. p. S259–S259.
Kang, Yubin, et al. “Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed/refractory multiple myeloma.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 23, 2023, pp. S259–S259.
Kang Y, Neff J, Gasparetto C, Wang X, Ellero A, Walker C. Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed/refractory multiple myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023. p. S259–S259.
Journal cover image

Published In

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

EISSN

2152-2669

ISSN

2152-2650

Publication Date

2023

Volume

23

Start / End Page

S259 / S259

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences